Nurix Therapeutics
NRIX
139 hedge funds and large institutions have $721M invested in Nurix Therapeutics in 2024 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 41 increasing their positions, 45 reducing their positions, and 17 closing their positions.
68% more call options, than puts
Call options by funds: $564K | Put options by funds: $335K
65% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 17
42% more capital invested
Capital invested by funds: $508M → $721M (+$213M)
7% more funds holding
Funds holding: 130 → 139 (+9)
9% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 45
1.07% less ownership
Funds ownership: 101.47% → 100.4% (-1.1%)
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$19.4M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$13.2M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.7M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$10.5M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.23M |
Top Sellers
NRIX Hedge Fund Activity: Q1 2024 in Review
139 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q1 2024, worth a combined $721M — up 42% from $508M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new NRIX positions and 17 closed out — a net gain of 11 holders — while 41 added to existing stakes and 45 trimmed.
The largest buyer was State Street, adding an estimated $19.4M. The largest seller was Morgan Stanley, cutting an estimated $40.2M.
- 139 institutional investors held Nurix Therapeutics (NRIX) as of Q1 2024, up from 130 in Q4 2023.
- Funds reported $721M of Nurix Therapeutics stock for Q1 2024, up 42% quarter-over-quarter.
- 28 funds opened new Nurix Therapeutics positions in Q1 2024 and 17 closed out, a net change of +11 holders.
- The largest Nurix Therapeutics buyer in Q1 2024 was State Street, an estimated $19.4M added.
- The largest Nurix Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $40.2M sold.
Based on aggregated 13F filings for Q1 2024.